StockData
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)

Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –

Spero Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Spero Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $19.58M. For fiscal 2025 it was -$12.62M. The highest annual figure on record is -$7.73M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.62M–
FY2024Dec 31, 2024-$23.44M–
FY2023Dec 31, 2023-$33.00M–
FY2022Dec 31, 2022-$7.73M–
FY2021Dec 31, 2021-$64.35M–
FY2020Dec 31, 2020-$85.87M–
FY2019Dec 31, 2019-$50.02M–
FY2018Dec 31, 2018-$39.63M–
FY2017Dec 31, 2017-$39.11M–
FY2016Dec 31, 2016-$28.96M–
FY2015Dec 31, 2015-$9.61M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.36M–
Q1 FY2026Mar 31, 2026$15.86M–
Q4 FY2025Dec 31, 2025-$8.35M–
Q3 FY2025Sep 30, 2025$17.42M+36.5%
Q2 FY2025Jun 30, 2025-$17.69M–
Q1 FY2025Mar 31, 2025-$4.00M-167.4%
Q4 FY2024Dec 31, 2024-$23.40M–
Q3 FY2024Sep 30, 2024$12.76M-19.8%
Q2 FY2024Jun 30, 2024-$18.74M–
Q1 FY2024Mar 31, 2024$5.94M–
Q4 FY2023Dec 31, 2023-$17.49M-139.3%
Q3 FY2023Sep 30, 2023$15.92M–
Q2 FY2023Jun 30, 2023-$18.56M–
Q1 FY2023Mar 31, 2023-$12.85M–
Q4 FY2022Dec 31, 2022$44.48M–
Q3 FY2022Sep 30, 2022-$957.00K–
Q2 FY2022Jun 30, 2022-$23.03M–
Q1 FY2022Mar 31, 2022-$28.22M–
Q4 FY2021Dec 31, 2021-$27.35M–
Q3 FY2021Sep 30, 2021-$4.95M–
Q2 FY2021Jun 30, 2021-$16.57M–
Q1 FY2021Mar 31, 2021-$15.48M–
Q4 FY2020Dec 31, 2020-$16.38M–
Q3 FY2020Sep 30, 2020-$21.26M–
Q2 FY2020Jun 30, 2020-$24.90M–
Q1 FY2020Mar 31, 2020-$23.33M–
Q4 FY2019Dec 31, 2019-$17.37M–
Q3 FY2019Sep 30, 2019-$9.66M–
Q2 FY2019Jun 30, 2019-$12.07M–
Q1 FY2019Mar 31, 2019-$10.92M–
Q4 FY2018Dec 31, 2018-$13.51M–
Q3 FY2018Sep 30, 2018-$5.51M–
Q2 FY2018Jun 30, 2018-$8.64M–
Q1 FY2018Mar 31, 2018-$11.96M–
Q4 FY2017Dec 31, 2017-$12.74M–
Q3 FY2017Sep 30, 2017-$10.52M–
Q2 FY2017Jun 30, 2017-$8.88M–
Q1 FY2017Mar 31, 2017-$6.98M–
Q4 FY2016Dec 31, 2016-$9.20M–

More Spero Therapeutics figures

See a number that looks wrong?